L P Quinn

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists
    Giancarlo Trani
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
    Bioorg Med Chem Lett 18:5698-700. 2008
  2. ncbi LABORAS: Initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviour
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
    J Neurosci Methods 130:83-92. 2003
  3. ncbi A novel behavioural registration system LABORAS and the social interaction paradigm detect long-term functional deficits following middle cerebral artery occlusion in the rat
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CMI9 5AW, UK
    Brain Res 1031:118-24. 2005
  4. ncbi Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, Harlow, Essex CM19 5AW, UK
    J Neurosci Methods 156:218-27. 2006
  5. ncbi A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
    J Neurosci Methods 164:43-9. 2007
  6. ncbi The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B
    L P Quinn
    Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, UK
    Br J Pharmacol 154:226-33. 2008
  7. ncbi Postsynaptic 5-HT1B receptors modulate electroshock-induced generalised seizures in rats
    Tania O Stean
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW
    Br J Pharmacol 144:628-35. 2005

Collaborators

Detail Information

Publications7

  1. ncbi Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists
    Giancarlo Trani
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
    Bioorg Med Chem Lett 18:5698-700. 2008
    ....
  2. ncbi LABORAS: Initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviour
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
    J Neurosci Methods 130:83-92. 2003
    ....
  3. ncbi A novel behavioural registration system LABORAS and the social interaction paradigm detect long-term functional deficits following middle cerebral artery occlusion in the rat
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CMI9 5AW, UK
    Brain Res 1031:118-24. 2005
    ..Transient MCAO in rats may therefore provide a pre-clinical model to investigate agents offering symptomatic relief for ischaemia-induced motor deficits and anxiety over time following injury...
  4. ncbi Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, Harlow, Essex CM19 5AW, UK
    J Neurosci Methods 156:218-27. 2006
    ..The data captured and analysed using LABORAS, suggests that the automated system is able to detect both pharmacologically and lesion-induced changes in behaviour of mice, reliably and efficiently...
  5. ncbi A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
    J Neurosci Methods 164:43-9. 2007
    ..The data described in the present study provides further evidence that functional deficits following an acute MPTP dosing schedule in mice can be quantified and are related to nigro-striatal dopamine function...
  6. ncbi The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B
    L P Quinn
    Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, UK
    Br J Pharmacol 154:226-33. 2008
    ....
  7. ncbi Postsynaptic 5-HT1B receptors modulate electroshock-induced generalised seizures in rats
    Tania O Stean
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW
    Br J Pharmacol 144:628-35. 2005
    ..7. Overall, these data demonstrate that stimulation of postsynaptic 5-HT1B receptors inhibits electroshock-induced seizure spread in rats...